Trial reportBJOG : an international journal of obstetrics and gynaecology2019
Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis.
Trial report in BJOG : an international journal of obstetrics and gynaecology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Placental growth factor (PLGF)-based testing to help diagnose suspected pre-eclampsia: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2026Pooled it
- How are maternal and fetal outcomes incorporated when measuring benefits of interventions in pregnancy? Findings from a systematic review of cost-utility analyses.Health and quality of life outcomes · 2024Pooled it
- Placental Growth Factor (PlGF)- Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment.Ontario health technology assessment series · 2023Pooled it
- Health Economic Evaluation Alongside Stepped Wedge Trials: A Methodological Systematic Review.PharmacoEconomics · 2021Pooled it
- Placental growth factor measurements in the assessment of women with suspected Preeclampsia: A stratified analysis of the PARROT trial.Pregnancy hypertension · 2021Trial
- Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis.BJOG : an international journal of obstetrics and gynaecology · 2019Trial
- Pre-Eclampsia and Maternal Cardiovascular Function: Insights Into Pathophysiology and Care (Scientific Impact Paper No. 79).BJOG : an international journal of obstetrics and gynaecology · 2026Article
- Cost Comparison of Repeat Placental Growth Factor-Based Testing in Women with Suspected Preterm Pre-eclampsia, Compared to Usual Care: The PARROT-2 Trial.PharmacoEconomics - open · 2026Article
- PRESHA - Preventing severe hypertensive adverse events in pregnancy and childbirth: a study protocol for establishing a prospective cohort study and biobank in urban Tanzania.Frontiers in global women's health · 2026Article
- Combined Effects of Methyldopa and Baicalein orPharmaceuticals (Basel, Switzerland) · 2022Article
- Diagnosis and Management of Preeclampsia: Suggested Guidance on the Use of Biomarkers.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2022Review
- Cost-Utility Analysis of Planned Early Delivery or Expectant Management for Late Preterm Pre-eclampsia (PHOENIX).PharmacoEconomics - open · 2022Article
- Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders.American journal of obstetrics and gynecology · 2022Review
- Clinical tools and biomarkers to predict preeclampsia.EBioMedicine · 2022Review
- Unravelling the potential of angiogenic factors for the early prediction of preeclampsia.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Review
- Combined Effects of Methyldopa and Flavonoids on the Expression of Selected Factors Related to Inflammatory Processes and Vascular Diseases in Human Placenta Cells-An In Vitro Study.Molecules (Basel, Switzerland) · 2021Article
- Recent advances in the diagnosis and management of pre-eclampsia.Faculty reviews · 2020Review
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
objectiveTo calculate the cost-effectiveness of implementing PlGF testing alongside a clinical management algorithm in maternity services in the UK, compared with current standard care.
designCost-effectiveness analysis.
settingEleven maternity units participating in the PARROT stepped-wedge cluster-randomised controlled trial. POPULATION: Women presenting with suspected pre-eclampsia between 20
methodsMonte Carlo simulation utilising resource use data and maternal adverse outcomes.
main outcome measuresCost per maternal adverse outcome prevented.
resultsClinical care with PlGF testing costs less than current standard practice and resulted in fewer maternal adverse outcomes. There is a total cost-saving of UK£149 per patient tested, when including the cost of the test. This represents a potential cost-saving of UK£2,891,196 each year across the NHS in England.
conclusionsClinical care with PlGF testing is associated with the potential for cost-savings per participant tested when compared with current practice via a reduction in outpatient attendances, and improves maternal outcomes. This economic analysis supports a role for implementation of PlGF testing in antenatal services for the assessment of women with suspected pre-eclampsia. TWEETABLE ABSTRACT: Placental growth factor testing for suspected pre-eclampsia is cost-saving and improves maternal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.